UBS Group Issues Positive Forecast for McKesson (NYSE:MCK) Stock Price

McKesson (NYSE:MCK) had its price target lifted by UBS Group from $1,200.00 to $1,250.00 in a research note issued to investors on Thursday,Benzinga reports. They currently have a buy rating on the stock.

A number of other analysts have also issued reports on MCK. Weiss Ratings upgraded shares of McKesson from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, September 4th. Wells Fargo & Company lifted their price objective on shares of McKesson from $812.00 to $933.00 and gave the company an “equal weight” rating in a report on Tuesday, August 11th. Evercore reaffirmed an “outperform” rating and set a $950.00 target price (down from $1,000.00) on shares of McKesson in a research note on Thursday, August 6th. TD Cowen upped their target price on shares of McKesson from $1,006.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Leerink Partners increased their target price on shares of McKesson from $1,070.00 to $1,200.00 and gave the stock an “outperform” rating in a report on Thursday. Fifteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,026.18.

McKesson Stock Up 0.6%

NYSE:MCK opened at $1,075.38 on Thursday. McKesson has a 52 week low of $723.68 and a 52 week high of $1,121.50. The stock’s fifty day moving average is $934.72 and its two-hundred day moving average is $866.92. The stock has a market capitalization of $125.38 billion, a price-to-earnings ratio of 27.65, a price-to-earnings-growth ratio of 2.13 and a beta of 0.27.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $11.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.72 by $0.96. McKesson had a negative return on equity of 235.48% and a net margin of 1.12%. The firm had revenue of $110.96 billion for the quarter, compared to the consensus estimate of $109.90 billion. During the same quarter in the previous year, the business earned $9.86 EPS. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. On average, sell-side analysts expect that McKesson will post 44.71 EPS for the current fiscal year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Tuesday, December 1st will be issued a dividend of $0.94 per share. The ex-dividend date is Tuesday, December 1st. This represents a $3.76 annualized dividend and a yield of 0.3%. McKesson’s dividend payout ratio is 9.67%.

Insider Buying and Selling at McKesson

In other McKesson news, Director Bradley E. Lerman sold 301 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $892.33, for a total value of $268,591.33. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the firm’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total transaction of $98,950.95. Following the completion of the sale, the chief accounting officer owned 521 shares in the company, valued at $464,445.45. The trade was a 17.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,812 shares of company stock valued at $1,794,182 in the last quarter. Corporate insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On McKesson

A number of institutional investors and hedge funds have recently modified their holdings of the company. King Luther Capital Management Corp grew its holdings in shares of McKesson by 1.6% during the third quarter. King Luther Capital Management Corp now owns 49,889 shares of the company’s stock worth $42,596,000 after buying an additional 793 shares in the last quarter. Bingham Private Wealth LLC raised its position in shares of McKesson by 4.2% in the third quarter. Bingham Private Wealth LLC now owns 577 shares of the company’s stock valued at $493,000 after buying an additional 23 shares during the last quarter. Maryland State Retirement & Pension System lifted its stake in shares of McKesson by 7.9% during the third quarter. Maryland State Retirement & Pension System now owns 7,190 shares of the company’s stock valued at $6,139,000 after buying an additional 527 shares during the period. Ritholtz Wealth Management lifted its stake in shares of McKesson by 6.3% during the third quarter. Ritholtz Wealth Management now owns 14,918 shares of the company’s stock valued at $12,737,000 after buying an additional 887 shares during the period. Finally, UNIVEST FINANCIAL Corp lifted its stake in shares of McKesson by 4.3% during the third quarter. UNIVEST FINANCIAL Corp now owns 675 shares of the company’s stock valued at $576,000 after buying an additional 28 shares during the period. Institutional investors and hedge funds own 85.07% of the company’s stock.

Key McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson reported adjusted EPS of $11.68, above analyst expectations of roughly $10.70, on revenue of $110.96 billion versus estimates of $109.9 billion. Revenue grew about 7.5% year over year. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40. Specialty-drug demand, GLP-1 distribution, higher prescription volumes and operating gains supported the outlook; McKesson also closed its $2.25 billion Precision Medicine Group acquisition, expanding its healthcare services business. McKesson Q2 2027 Earnings Call Highlights
• Positive Sentiment: Analyst sentiment was broadly constructive: TD Cowen, Leerink Partners and Evercore ISI raised price targets to $1,200, while Deutsche Bank lifted its target to $1,120. RBC also praised McKesson’s execution. TD Cowen Raises McKesson Price Target
• Neutral Sentiment: EVP Francisco Fraga sold 600 shares under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, retaining 5,064 shares. SEC Filing
• Negative Sentiment: RBC’s “sector perform” rating and $965 price target—despite an increase from its prior target—indicate a more cautious view and imply downside from the recent share price. RBC on McKesson’s Execution

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.